Thornal Kevin R sold $529K of ZBH

Thornal Kevin R (Grp Pres-Global Business) sold 5,691 shares of ZIMMER BIOMET HOLDINGS, INC. (ZBH) at $92.95 ($0.53M total) on 2026-09-11.

Original reporting
SEC EDGAR · Thornal Kevin R
Published Sep 15, 2026, 8:24 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 15, 2026, 8:45 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ZBH
Bearish
high confidence
Mentioned
$ZBH
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ZBHBearishLow
01

Why it matters

The insider's complete exit could be interpreted as a lack of confidence, but the modest amount limits market reaction.

02

Market read

Minor insider sale; unlikely to affect ZBH price materially.

03

What to watch

Potential tax‑loss harvesting or personal liquidity needs could drive the transaction.

Relevance 5/10Novelty 3/10Timing: filed today

Background

SEC Form 4 filings disclose insider transactions; traders monitor them for signals.

Company-level read

Ticker impact

$ZBHBearishHigh confidence
Context

Officer Thornal Kevin R sold 5,691 shares of ZBH for $528,978 on 2026-09-11.

Expected impact

Minimal short‑term pressure; unlikely to move the stock materially.

Evidence & confidence

The sale size (~$0.5 M) is small relative to market cap; insider exits can signal concern but the amount is not material.

Market effects

Limited; does not affect broader orthopedic device sector.

None; confined to ZBH shareholders.

Low; no cross‑market ripple.

Counterpoint

The sale may be routine portfolio rebalancing rather than a negative signal.

Key entities

  • Zimmer Biomet Holdings, Inc.

    Medical device manufacturer listed on NYSE under ZBH.

  • Thornal Kevin R

    Group President – Global Business, officer of ZBH.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ZBHMed

What Zimmer Biomet (ZBH) Said on Its Q3 Earnings Call

Zimmer Biomet (ZBH) reported Q3 sales growth of 13% in technology, bone cement, and surgical sales, but a 2.6% decline in global knee sales. CEO Tornos attributed knee underperformance to commercial execution. The company expects to launch its Monogram robotic system in early 2027. Q3 adjusted earnings were $1.90 per share, with margins declining but cash flow rising. Full-year sales growth guidance was raised to 4.4%-4.9%.

$ZBHMed

Truist raises Zimmer Biomet stock price target on robotics progress

Truist Securities raised Zimmer Biomet's (ZBH) price target to $114 from $106, citing 3.7% Q3 organic revenue growth, though EPS missed estimates. The stock is up 13% in a week. Analysts note progress in robotics and hip segments, but caution on knee division weakness and future risks. Other analysts also raised targets, with Stifel at $125 and Jefferies at $120.

$ZBHMed

Zimmer Biomet Holdings Inc (ZBH) (Q3 2026) Earnings Call Highlights: Guidance Raised as Hips

Zimmer Biomet (ZBH) reported Q3 2026 earnings, raising guidance despite a 2.6% decline in knee business due to sales force transition and competitive pressure. Adjusted operating margin fell 140 basis points to 25.1%, and gross margin decreased 90 basis points to 71.7%. CEO Ivan Tornos highlighted sustainable growth in hips and S.E.T. areas, but acknowledged underperformance in knees. China headwinds and sales force disruption pose risks.